mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2019-4-96-98mrj-965Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSОпыт применения метотрексата у пациента с болезнью депонирования кристаллов пирофосфата кальцияExperience with methotrexate in a patient with calcium pyrophosphate crystal deposition diseaseИльиныхЕ. В.IlyinykhE. V.

Екатерина Валериевна Ильиных

115522, Москва, Каширское шоссе, 34А

Ekaterina Valerievna Ilyinkh

34A, Kashirskoe Shosse, Moscow 115522

kater1104@yahoo.comЕлисеевМ. С.EliseevM. S.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation2019231020191349698Copyright © Ильиных Е.В., Елисеев М.С., 20192019Ильиных Е.В., Елисеев М.С.Ilyinykh E.V., Eliseev M.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/965

В статье обсуждаются результаты применения в реальной клинической практике метотрексата (МТ) у пациента с болезнью депонирования кристаллов пирофосфата кальция, резистентного к терапии традиционными противовоспалительными препаратами (колхицин, нестероидные противовоспалительные препараты, гидроксихлорохин). Продемонстрированы эффективность и возможность безопасного назначения МТ в дозе 20 мг/нед на протяжении года.

The paper discusses the results of using methotrexate (MTX) in real clinical practice in a patient with calcium pyrophosphate crystal deposition resistant to traditional anti-inflammatory drugs (colchicine, nonsteroidal anti-inflammatory drugs, and hydroxychloroquine) It demonstrates the efficiency and possibility of safely using MTX at a dose of 20 mg/week during a year.

пирофосфатная артропатияболезнь депонирования кристаллов пирофосфата кальцияхронический артритметотрексатколхицингидроксихлорохиннестероидные противовоспалительные препаратыpyrophosphate arthropathycalcium pyrophosphate crystal deposition diseasechronic arthritismethotrexatecolchicinehydroxychloroquinenonsteroidal anti-inflammatory drugsReferencesJohnson K, Terkeltaub R. Inorganic pyrophosphate (PPI) in pathologic calcification of articular cartilage (review). Front Biosci. 2005 Jan 1;10:988-97. Print 2005 Jan 1.Johnson K, Terkeltaub R. Inorganic pyrophosphate (PPI) in pathologic calcification of articular cartilage (review). Front Biosci. 2005 Jan 1;10:988-97. Print 2005 Jan 1.Барскова ВГ. Диагностика болезни депонирования кристаллов пирофосфата кальция (пирофосфатной артропатии). Русский медицинский журнал. 2012;(7): 350-3.Barskova VG. Diagnosis of calcium pyrophosphate crystal deposition disease (pyrophosphate arthropathy). Russkii meditsinskii zhurnal. 2012;(7):350-3. (In Russ.).Zhang W, Doherty M, Bardin T, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011 Apr;70(4):563-70. doi: 10.1136/ard.2010.139105. Epub 2011 Jan 7.Zhang W, Doherty M, Bardin T, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011 Apr;70(4):563-70. doi: 10.1136/ard.2010.139105. Epub 2011 Jan 7.Tedeschi SK. Issues in CPPD Nomenclature and Classification. Curr Rheumatol Rep. 2019 Jul 25;21(9):49. doi: 10.1007/s11926-019-0847-4.Tedeschi SK. Issues in CPPD Nomenclature and Classification. Curr Rheumatol Rep. 2019 Jul 25;21(9):49. doi: 10.1007/s11926-019-0847-4.Bencardino JT, Hassankhani A. Calcium pyrophosphate dihydrate crystal deposition disease. Semin Musculoskelet Radiol. 2003 Sep;7(3):175-85.Bencardino JT, Hassankhani A. Calcium pyrophosphate dihydrate crystal deposition disease. Semin Musculoskelet Radiol. 2003 Sep;7(3):175-85.Abhishek A, Doherty M. Update on calcium pyrophosphate deposition. Clin Exp Rheumatol. 2016 Jul-Aug;34(4 Suppl 98): 32-8. Epub 2016 Jul 22.Abhishek A, Doherty M. Update on calcium pyrophosphate deposition. Clin Exp Rheumatol. 2016 Jul-Aug;34(4 Suppl 98): 32-8. Epub 2016 Jul 22.Zhang W, Doherty M, Bardin T, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part II: managment. Ann Rheum Dis. 2011 Apr;70(4):571-5. doi: 10.1136/ard.2010.139360. Epub 2011 Jan 20.Zhang W, Doherty M, Bardin T, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part II: managment. Ann Rheum Dis. 2011 Apr;70(4):571-5. doi: 10.1136/ard.2010.139360. Epub 2011 Jan 20.Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol. 1986 Aug;13(4):804-5.Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol. 1986 Aug;13(4):804-5.Владимиров СА, Елисеев МС. Современная стратегия лечения болезни депонирования кристаллов пирофосфата кальция. Научно-практическая ревматология. 2018;56(6):746-52. doi: 10.14412/1995-4484-2018-746-752Vladimirov SA, Eliseev MS. Current strategy in the treatment of calcium pyrophosphate crystal deposition disease. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56(6):746-52. (In Russ.). doi: 10.14412/1995-4484-2018-746-752Chollet-Janin A, Finckh A, Dudler J, et al. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum. 2007 Feb;56(2):688-92.Chollet-Janin A, Finckh A, Dudler J, et al. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum. 2007 Feb;56(2):688-92.Елисеев МС, Владимиров СА, Насонов ЕЛ. Применение метотрекаста у больных с болезнью депонирования кристаллов пирофосфата кальция. Научно-практическая ревматология. 2018;56(2): 196-201. doi: 10.14412/1995-4484-2018-196-201Eliseev MS, Vladimirov SA, Nasonov EL. Use of methotrexate in patients with calcium pyrophosphate crystal deposition disease. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56(2):196-201. (In Russ.). doi: 10.14412/1995-4484-2018-196-201Doan TH, Chevalier X, Leparc JM, et al. Premature enthusiasm for the use of methotrexate for refractory chondrocalcinosis: comment on the article by Chollet-Janin et al. Arthritis Rheum. 2008 Jul;58(7): 2210-1. doi: 10.1002/art.23552.Doan TH, Chevalier X, Leparc JM, et al. Premature enthusiasm for the use of methotrexate for refractory chondrocalcinosis: comment on the article by Chollet-Janin et al. Arthritis Rheum. 2008 Jul;58(7): 2210-1. doi: 10.1002/art.23552.Finckh A, Mc Carthy GM, Madigan A, et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther. 2014 Oct 15;16(5): 458. doi: 10.1186/s13075-014-0458-4.Finckh A, Mc Carthy GM, Madigan A, et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther. 2014 Oct 15;16(5): 458. doi: 10.1186/s13075-014-0458-4.Andres M, Sivera F, Pascual E. Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis. J Clin Rheumatol. 2012 Aug;18(5): 234-6. doi: 10.1097/RHU.0b013e3182611471.Andres M, Sivera F, Pascual E. Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis. J Clin Rheumatol. 2012 Aug;18(5): 234-6. doi: 10.1097/RHU.0b013e3182611471.Cheung HS. Calcium crystal effects on the cells of the joint: implications for pathogenesis of disease. Curr Opin Rheumatol. 2000 May;12(3):223-7.Cheung HS. Calcium crystal effects on the cells of the joint: implications for pathogenesis of disease. Curr Opin Rheumatol. 2000 May;12(3):223-7.Dalbeth N, Haskard DO. Inflammation and tissue damage in crystal deposition diseases. Curr Opin Rheumatol. 2005 May;17(3): 314-8.Dalbeth N, Haskard DO. Inflammation and tissue damage in crystal deposition diseases. Curr Opin Rheumatol. 2005 May;17(3): 314-8.Cheung HS. Biologic effects of calciumcontaining crystals [review]. Curr Opin Rheumatol. 2005 May;17(3):336-40.Cheung HS. Biologic effects of calciumcontaining crystals [review]. Curr Opin Rheumatol. 2005 May;17(3):336-40.Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005 Jun;57(2):163-72.Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005 Jun;57(2):163-72.Seitz M. Molecular and cellular effects of methotrexate [review]. Curr Opin Rheumatol. 1999 May;11(3):226-32.Seitz M. Molecular and cellular effects of methotrexate [review]. Curr Opin Rheumatol. 1999 May;11(3):226-32.Weinblatt ME, Polisson R, Blotner SD, et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis: results of a 36-week randomized trial comparing methotrexate and auranofin [published erratum appears in Arthritis Rheum 1993; 36:1028]. Arthritis Rheum. 1993 May;36(5): 613-9.Weinblatt ME, Polisson R, Blotner SD, et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis: results of a 36-week randomized trial comparing methotrexate and auranofin [published erratum appears in Arthritis Rheum 1993; 36:1028]. Arthritis Rheum. 1993 May;36(5): 613-9.Finckh А, Mc Carthy GM, Madigan A. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther. 2014 Oct 15;16(5):458. doi: 10.1186/s13075-014-0458-4.Finckh А, Mc Carthy GM, Madigan A. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther. 2014 Oct 15;16(5):458. doi: 10.1186/s13075-014-0458-4.Campillo-Gimenez L, Renaudin F, Jalabert M, et al. Inflammatory Potential of Four Different Phases of Calcium Pyrophosphate Relies on NF-κB Activation and MAPK Pathways. Front Immunol. 2018 Oct 9;9:2248. doi: 10.3389/fimmu.2018.02248. eCollection 2018.Campillo-Gimenez L, Renaudin F, Jalabert M, et al. Inflammatory Potential of Four Different Phases of Calcium Pyrophosphate Relies on NF-κB Activation and MAPK Pathways. Front Immunol. 2018 Oct 9;9:2248. doi: 10.3389/fimmu.2018.02248. eCollection 2018.

The authors declare that there are no conflicts of interest present.